Not of Standard Quality drug

Indian Economy glossary

FlashcardsQuick reviseKey facts. One by one.Start →

Also called: NSQ, Substandard drug · Topic: Consumer Rights and Consumer Protection · NCERT: Beyond NCERT

Meaning

A Not of Standard Quality (NSQ) drug (also called a substandard drug) is a genuine, authorised medicine that fails one or more of its set quality specifications when a lab tests it. A falsified (spurious) drug is different: it deliberately lies about its identity, composition or source.

NSQ drugs matter because the patient cannot see the defect. A tablet with too little medicine or an injection that is not sterile looks normal. Only state testing can catch it. This is a clear case of the consumer's right to safety.

Explanation

How a drug is declared NSQ

  • The rule-book: the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 made under it.
  • The sample: inspectors draw samples, mostly from the market. So by the time a batch is found NSQ, it has often already reached patients.
  • The test: a Government Analyst (a state-appointed drug-testing officer) tests the sample. The result is recorded in Form 13, the Government Analyst's report.
  • What happens next:
  • Recall: the manufacturer is told to recall the product at once and stop distribution.
  • Licence action: after investigation, the authority may order a stop to production, suspend or cancel the licence, or issue a warning letter or show-cause notice (a notice asking the firm to explain itself).
  • Public alert: CDSCO publishes NSQ results as monthly drug alerts.

  • Right to challenge: under Section 25 of the 1940 Act, a person can contest the Government Analyst's report and ask for the sample to be sent to the Central Drugs Laboratory (CDL). The CDL's report is conclusive evidence, meaning final.

Types of quality failure

Some failures harm patients directly. These are the five critical parameters:

  • Assay: whether the drug has the right amount of active ingredient. Too little means under-dosing.
  • Dissolution: whether the tablet breaks down and releases the drug in the body as it should.
  • Related substances and impurities: unwanted chemicals in the product.
  • Sterility: whether the product is free of germs. This is vital for injectables.

Other failures, such as labelling or description defects, are less serious. They are not on the critical list.

Why NSQ drugs are harmful

  • Treatment failure: the patient takes the medicine but does not get better.
  • Direct toxicity: impurities or contamination can poison the patient.
  • Antimicrobial resistance (AMR): an antibiotic with too little active ingredient kills only the weaker germs, so the stronger ones survive and spread.
  • The economics: this is information asymmetry. The maker knows the quality but the buyer cannot check it. So the market alone cannot punish bad quality, and the state must test.

Worked example: the NSQ rate

  • In 2024-25, State/UT labs tested 1,16,323 samples and found 3,104 NSQ.
  • NSQ rate = 3,104 ÷ 1,16,323 × 100 ≈ 2.7%.
  • In 2023-24 the figures were 2,988 out of 1,06,150, which is about 2.8%.
  • What this shows: about 27 of every 1,000 samples failed. The rate has barely changed even though testing grew.

In India

  • Who regulates:
  • CDSCO, the central regulator headed by the DCGI;
  • the State Drugs Controllers.
  • Licensing is split between the Central Licensing Approving Authority and the State Licensing Authorities.

  • Why coordination is hard: the State where a sample is tested is often not the State where the drug was made. Many drugs are also sold by a marketer rather than the maker.

  • Latest data (2024-25): 3,104 NSQ samples and 245 spurious or adulterated samples, out of 1,16,323 tested.
  • Inspections: from December 2022, CDSCO and State regulators ran risk-based inspections, covering 960+ premises with 860+ regulatory actions.
  • Prevention at the factory stage:
  • Revised Schedule M, the Good Manufacturing Practice (GMP) rules, was notified on 28 December 2023 in line with WHO standards.
  • Large firms had to comply from June 2024.
  • MSMEs (turnover up to ₹250 crore) got a conditional extension to 31 December 2025.

  • Proposed tougher rule: a draft amendment to the Drugs Rules, 1945 proposes immediate licence suspension when a drug is NSQ on any of the five critical parameters.

  • The suspension would be lifted only after the firm completes a Root Cause Analysis (RCA), which finds the cause, and a Corrective and Preventive Action (CAPA) plan, which fixes it and stops it recurring.
  • The Licensing Authority must verify both.

  • Capacity gaps:

  • A Parliamentary Standing Committee on Health found persistent vacancies among Drugs Controllers.
  • A CAG audit of Andhra Pradesh found 11 of 59 sanctioned Drug Inspector posts vacant.

  • Global picture: WHO launched its Global Surveillance and Monitoring System (GSMS) for substandard and falsified products in 2013. WHO (2017) estimates that about 1 in 10 medical products in low- and middle-income countries is substandard or falsified.

Don't confuse with

  • Spurious / falsified drug: made to deceive about its identity, composition or source. An NSQ drug is a genuine, licensed product that failed a test.
  • Adulterated drug: contains a harmful or foreign substance. Official data counts it with spurious drugs, separately from NSQ (245 spurious or adulterated vs 3,104 NSQ in 2024-25).
  • Schedule M (GMP): a preventive rule for how a factory must make drugs. NSQ is a detection finding made after testing a sample.
  • DPCO price ceiling: NPPA's price cap controls the price of essential medicines. NSQ is about quality, under the Drugs and Cosmetics Act, 1940.

Prelims Hooks

  • NSQ means a genuine, authorised product that fails quality specifications. Falsified means a product that deliberately misrepresents its identity, composition or source.
  • The Government Analyst's report is filed in Form 13 under the Drugs Rules, 1945.
  • Under Section 25 of the D&C Act, 1940, the report can be contested, and the Central Drugs Laboratory's report is conclusive.
  • The five critical NSQ parameters are Assay, Dissolution, Related Substances, Impurities and Sterility. Labelling failures are not among them.
  • CDSCO publishes NSQ results as monthly drug alerts.
  • WHO's GSMS for substandard and falsified products started in 2013. Revised Schedule M was notified on 28 December 2023.

Mains Points

  • Due process vs patient safety:
  • Suspending a licence on the first lab report protects patients fast, especially against sterility and assay failures.
  • But the CDL retest under Section 25 comes later, and government labs have weak spots such as non-validated methods and staff shortages.
  • A balanced answer: keep the rule, but set fixed deadlines for the CDL retest and the RCA/CAPA review.

  • Testing capacity decides enforcement:

  • Vacancies among Drugs Controllers and Drug Inspectors slow testing, re-inspection and restarting.
  • Because samples come from the market, real protection depends on prevention at the factory through Schedule M, not only punishment after sale.

  • Consumer protection and the "pharmacy of the world":

  • NSQ drugs violate the consumer's right to safety and show the information-asymmetry failure of markets.
  • After the cough-syrup cases, proven quality (Schedule M compliance, post-marketing surveillance, outside benchmarking) decides India's export credibility.
  • Federal angle: Centre–State coordination through a shared Form 13 matters as much as new powers.

Read more